Related Experiment Video
Updated: Jan 30, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Immune therapy of melanoma: Overview of therapeutic vaccines
Zahra Payandeh1, Maral Yarahmadi2, Ziba Nariman-Saleh-Fam3
1Immunology Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Melanoma is the most serious type of skin cancer which develops from the occurrence of genetic mutations in the melanocytes. Based on the features of melanoma tumors such as location, genetic profile and stage, there are several therapeutic strategies including surgery, chemotherapy, and radiotherapy. However, because of the appearance resistance mechanisms, the efficiency of these treatments strategies may be reduced. It has been demonstrated that therapeutic monoclonal antibodies can improve the efficiency of melanoma therapies. Recently, several mAbs, such as nivolumab, pembrolizumab, and ipilimumab, were approved for the immunotherapy of melanoma. The antibodies inhibit immune checkpoint receptors such as CTL4 and pd-1. Another therapeutic strategy for the treatment of melanoma is cancer vaccines, which improve clinical outcomes in patients. The combination therapy using antibodies and gene vaccine give us a new perspective in the treatment of melanoma patients. Herein, we present the recent progressions in the melanoma immunotherapy, especially dendritic cells mRNA vaccines by reviewing recent literature.
Insights
Melanoma immunotherapy shows promise with new strategies like monoclonal antibodies and dendritic cell mRNA vaccines, offering improved treatment options for patients. These advanced therapies target immune checkpoints to enhance anti-cancer responses.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Melanoma, a severe skin cancer, arises from genetic mutations in melanocytes.
- Conventional treatments (surgery, chemotherapy, radiotherapy) face resistance, limiting efficacy.
- Therapeutic monoclonal antibodies (mAbs) and cancer vaccines are emerging as effective melanoma treatments.
Purpose of the Study:
- To review recent advancements in melanoma immunotherapy.
- To highlight the potential of dendritic cell mRNA vaccines in combination therapy.
- To explore novel therapeutic strategies for melanoma treatment.
Main Methods:
- Literature review of recent scientific publications on melanoma immunotherapy.
- Analysis of therapeutic monoclonal antibodies targeting immune checkpoints (e.g., CTLA-4, PD-1).
- Evaluation of cancer vaccines, particularly dendritic cell mRNA vaccines.
Main Results:
- Approved mAbs (nivolumab, pembrolizumab, ipilimumab) demonstrate efficacy by inhibiting immune checkpoints.
- Cancer vaccines show potential for improving clinical outcomes in melanoma patients.
- Combination therapy with antibodies and gene vaccines offers a promising new approach.
Conclusions:
- Immunotherapy, including mAbs and dendritic cell mRNA vaccines, represents a significant progression in melanoma treatment.
- Combination strategies hold substantial potential for enhancing therapeutic responses and patient outcomes.
- Further research into these novel immunotherapies is warranted for improved melanoma management.
Related Concept Videos
01:51Vaccinations
01:16Therapeutic Drug Monitoring: Overview and Classification
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:38What is the Immune System?
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
00:59Gene Therapy